



## **NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate**

***Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support Networks***

Cleveland, OH – November 22, 2022 -- NovAccess Global Inc. (OTCQB: XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.

The fireside chat announced today is an interview conducted by NovAccess Global CEO Dr. Dwain Irvin with cancer patient advocate Cori Freeman. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at <https://novaccessglobal.com/news/> and on all of the Company's social media feeds.

During the interview made available today, the speakers highlight:

- ***Journeys through treatment for patients, their support systems and families***
- ***Failures and challenges of traditional/conventional chemotherapy, where cancers often "came back with a vengeance"***
- ***Choosing the appropriate treatment options for brain tumor/glioblastoma patients***
- ***Benefits of building up the immune system with immunotherapy when fighting cancer***
- ***Integrative approaches with immunotherapy***
- ***NovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumors***
- ***Hope found with glioblastoma immunotherapy research by Dr. Dwain Irvin***
- ***Success stories of recovery after traditional chemotherapy using immunotherapy***
- ***Improving the quality of life for patients and accelerating the path to recovery***

- ***20 years of clinical trials as the foundation for NovAccess Global's lead drug candidate TLR-AD1 which recently received FDA approval for Orphan Drug Designation***
- ***NovAccess Global leveraging new technologies, additional assets, novel therapies and diagnostic data as it pursues IND for new clinical trials***

#### **NovAccess Global Fireside Chat Series Schedule:**

The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as detailed below:

#### ***October 6, 2022 – NovAccess Global Board Member Perspectives – Opportunities for the Biomedical Field and for Shareholders***

Speakers: Select Executive and Non-Executive members of the Company's Board of Directors

#### ***November 18, 2022 – Patient Advocacy***

Speakers: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global; cancer patient advocate Cori Freeman

#### ***December 2022 – Immunotherapy Advantages Over Surgical Treatment***

Speaker: Dr. Christopher Wheeler, Ph.D., President of StemVax Therapeutics Inc., a division of NovAccess Global

#### ***January 2023 – The Glioblastoma and Brain Tumor Market***

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

The interviews will be streamed for public viewing over the Internet and can be accessed on the dates provided in this press release through links made available on the NovAccess Global website at [www.novaccessglobal.com](http://www.novaccessglobal.com) and on all of the Company's social media feeds.

#### **About NovAccess Global**

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like

receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit [novaccessglobal.com](http://novaccessglobal.com).

### **Forward-Looking Statement**

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

This press release and the interviews to be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell, or a solicitation of an offer to buy any security. Interview participants have agreed to participate in this event series and no compensation will be paid or furnished to them or their respective organizations. Participation does not represent an offer to buy or sell any security to or from any person or other entity through their platforms. Prior to making any investment or subscribing to any of the platforms that may be associated with the fireside chat series and redistribution of related content, listeners/viewers are encouraged to consult with professional financial, legal advisor and tax advisors to assist in due diligence as may be appropriate in determining the risk associated with any investment.

### **Investor Relations Contact:**

Jordan Darrow  
Darrow Associates  
631-766-4528  
[jdarrow@darrowir.com](mailto:jdarrow@darrowir.com)